Physician profile
Timothy Mark Ashburn
NPI 1417242264
$6,905.02
in general payments reported to CMS, 2019-2025
30 companies · $1,580 in 2025
The $1,580 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,302 · 2020: $755 · 2021: $1,612 · 2022: $488 · 2023: $472 · 2024: $696 · 2025: $1,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,732 · Education: $16.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,731.94 |
| Education | $16.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,254.21 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $730.35 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $710.84 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Grifols USA, LLC | $507.54 | 2019-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $338.37 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $319.74 | 2020-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Hospital Products INC. | $298.55 | 2020-2022 | |
| Insmed, INC. | $257.93 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $225.34 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $199.85 | 2019-2021 | |
| Circassia INC. | $152.66 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $150.70 | 2021-2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $121.53 | 2024-2025 | Dupixent |
| Mallinckrodt Enterprises LLC | $108.81 | 2019 | |
| Ani Pharmaceuticals, INC. | $83.08 | 2023-2024 | Purified Cortrophin Gel |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $65.00 | 2024-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $49.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $47.57 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $37.43 | 2023 | Nuzyra |
| Baxter Healthcare | $36.89 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Shire North American Group INC | $31.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.32 | 2022-2023 | Glassia |
| Mylan Specialty L.P. | $28.50 | 2019-2021 | |
| Viatris Specialty LLC | $19.41 | 2025 | Yupelri |
| Lilly USA, LLC | $18.21 | 2025 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $17.95 | 2025 | Eliquis |
| Amgen INC. | $17.57 | 2022 | |
| Gilead Sciences, INC. | $15.89 | 2021 | |
| Pulmonx Corporation | $15.82 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Boston Scientific Corporation | $15.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ashburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.